MERCY OSAGHAE: Open Payments
NPI 1972169332 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,413 in 103 payments from 14 companies in 2025. Trend: 2023 $954 · 2024 $1,519 · 2025 $2,413
Food & beverage: $2,301Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $384 |
| Otsuka America Pharmaceutical, Inc. | 13 | $328 |
| Teva Pharmaceuticals USA, Inc. | 12 | $316 |
| ABBVIE INC. | 22 | $284 |
| Alkermes, Inc. | 7 | $223 |
| E.R. Squibb & Sons, L.L.C. | 7 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $210 |
| Supernus Pharmaceuticals, Inc. | 7 | $195 |
| Collegium Pharmaceutical, Inc. | 1 | $63 |
| Axsome Therapeutics, Inc. | 3 | $55 |
Products named: REXULTI, VRAYLAR, ARISTADA, COBENFY, CAPLYTA, Qelbree, AUSTEDO XR, INGREZZA.
Industry payments across TX — which companies pay providers there.
